How effective is the obesity treatment on improving oxidative stress? Is there any difference between drugs?

Basit Öğe Kaydı
dc.contributor.authorKeskin, Lezan
dc.contributor.authorŞahin, İbrahim
dc.contributor.authorYavuz, Dilek Gogas
dc.contributor.authorYüksel, Meral
dc.contributor.authorTaşkapan, Mehmet Çağatay
dc.date.accessioned2024-08-04T19:53:27Z
dc.date.available2024-08-04T19:53:27Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction: Obesity shortens the life period and decreases its quality, causing several complications. Recently, oxidative stress produced by lipid peroxydation is considered a cardiovascular risk factor. In this study, we aimed to investigate the relationship between weight loss with lipid profile, insulin resistance, and lipid peroxidation products malondialdehyde (MDA, oxidant) and paraoxonase-1 (PON1, antioxidant) levels which is protective in atherosclerosis, and to evaluate alteration on oxidative stress. Methods: Patients diagnosed as obese at the Endocrinology and Metabolic Diseases Outpatient Clinics of Inonu University Faculty of Medicine between December 2005 and February 2008 were studied. 103 patients were included in the study. Study population was divided into two treatment groups. In the first group, 120 mg of orlistat, three times daily, and in the second group, sibutramine 15 mg per day were given in addition to appropriate diet therapy. The patients were evaluated at the end of three months treatment period. Results: Dramatic changes in body weight, Body Mass Index (BMI), and waist and hip circumference were observed during the three-month evaluation in patients receiving orlistat or sibutramine. Additionally, significant improvements were measured in systolic- diastolic blood pressure levels, lipid levels, and insulin resistance. The decrease in the MDA level and the increase in the PON level were similar and significant in both patient groups. Discussion and Conclusion: The treatment of obesity, aimed at reducing body weight, acts to reduce oxidative stress by increasing paraoxonase-1 activity (antioxidant) and reducing the amount of the peroxidation product malondialdehyde (oxidant), regardless of the type of medication administered.en_US
dc.identifier.doi10.54307/NWMJ.2022.36855
dc.identifier.endpage83en_US
dc.identifier.issn2757-7724
dc.identifier.issue2en_US
dc.identifier.startpage75en_US
dc.identifier.trdizinid1166581en_US
dc.identifier.urihttps://doi.org/10.54307/NWMJ.2022.36855
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1166581
dc.identifier.urihttps://hdl.handle.net/11616/89784
dc.identifier.volume2en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofNorthwestern Medical Journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleHow effective is the obesity treatment on improving oxidative stress? Is there any difference between drugs?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu